Literature DB >> 751719

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy.

J M Denefrio, D R East, M B Troner, C L Vogel.   

Abstract

The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 751719

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  4 in total

1.  Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

Authors:  L Rausa; A Russo; V Gebbia; N Gebbia; N D'Alessandro; S Palmeri
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.

Authors:  A Sulkes; E Gez; M R Pfeffer; R Catane; R Isacson; S Biran
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

3.  Effective second line chemotherapy of advanced breast cancer with navelbine and mitomycin C.

Authors:  W Scheithauer; G Kornek; K Haider; W Kwasny; T Schenk; R Pirker; D Depisch
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil (CNF) versus cyclophosphamide, adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer.

Authors:  M C Alonso; J M Tabernero; B Ojeda; M Llanos; C Solà; M A Climent; M A Seguí; J J López
Journal:  Breast Cancer Res Treat       Date:  1995-04       Impact factor: 4.872
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.